Answers are grounded in this paper and cite their sources.
Background: Vitis carnosa Wall., commonly known as Gomikanda (GK), is an Ayurvedic medicinal plant traditionally used for managing digestive, inflammatory, and blood-related disorders. Despite its historical usage, systematic evaluation of its anticancer potential remains scarce. Objective: The objective of this study was to investigate the in vitro cytotoxic activity of GK extract against a panel of human cancer cell lines using the sulforhodamine B assay, with Adriamycin (ADR) as a positive control. Materials and Methods: GK aqueous extract was tested at concentrations of 10, 20, 40, and 80 μg/mL against K-562 (leukemia), MCF-7 and MDA-MB-231 (breast cancer), A-498 (kidney cancer), COLO-205 (colon cancer), and SK-OV-3 (ovarian cancer) cell lines. Growth inhibition was expressed as percentage control growth, and GI 50 , TGI, and LC 50 values were calculated. Results: GK exhibited mild-to-moderate cytotoxicity in select cell lines, with the most notable effect in K-562 cells (79.5% control growth at 80 μg/mL (71%–84% range across mid-high doses) and MCF-7 cells (~80%–83% growth at 40–80 μg/mL). Mild inhibition was noted in A-498, MDA-MB-231, and COLO-205, while SK-OV-3 displayed borderline mild activity. GI 50 values exceeded 80 μg/mL for all tested lines, indicating low potency compared to ADR, which showed GI 50 <10 μg/mL in all cases. Conclusion: GK demonstrates measurable but limited cytotoxic potential, with activity varying by cancer type. Although not potent as a standalone chemotherapeutic, its mild inhibitory profile and probable safety support further studies on its chemopreventive or adjunctive role in integrative oncology, including phytochemical, mechanistic, synergy, and in vivo evaluations.
No takes yet. Share an insight, caveat, or question.
Jangid et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: